Contact us:
+1 (520) 226-8615
Email:
[email protected]

IHP 310-Drug Development and Ethical Considerations Chapter 01
McCuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 9th Edition
MULTIPLE CHOICE
| a. | “Participation for the duration of the study is required.” |
| b. | “Participation may end at any time without penalty.” |
| c. | “Withdrawal from the study may end at any time, but the gift certificate will not be given.” |
| d. | “You can request placement in the treatment group.” |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 3
TOP: Nursing Process: Nursing Intervention
MSC: NCLEX: Management of Client Care
| a. | autonomy. |
| b. | beneficence. |
| c. | justice. |
| d. | veracity. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 3
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | Beneficence |
| b. | Justice |
| c. | Respect for persons |
| d. | Veracity |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | Beneficence |
| b. | Justice |
| c. | Respect for persons |
| d. | Veracity |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
IHP 310-Drug Development and Ethical Considerations
| a. | are selected for participation in that group. |
| b. | have unique baseline characteristics. |
| c. | receive a placebo. |
| d. | receive the treatment being evaluated. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 6
TOP: Nursing Process: Nursing Intervention: Patient Teaching
MSC: NCLEX: Management of Client Care
| a. | Ask the patient to clarify concerns. |
| b. | Reinforce that cash is given to all subjects equally. |
| c. | Report this statement to the party named on the consent. |
| d. | Review the elements of the study and obtain consent. |
ANS:
DIF: Cognitive Level: Applying (Application) REF: p. 3
TOP: Nursing Process: Nursing Intervention
MSC: NCLEX: Management of Client Care
| a. | A comparison of experimental and control data in animals |
| b. | A study conducted in a test tube in a laboratory |
| c. | A study that determines the effects of the placebo in human participants |
| d. | A study to assess the seriousness of the disease to be treated |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | did not pass through the appropriate phases of clinical trials. |
| b. | did not require human subject protections and are invalid. |
| c. | were not tested on women, minorities, or children. |
| d. | were tested on healthy subjects only. |
ANS: C
Drug research was historically done only with Caucasian males, causing uncertainty as to the validity of the research results.
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | Phase I |
| b. | Phase II |
| c. | Phase III |
| d. | Phase IV |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
IHP 310-Drug Development and Ethical Considerations
| a. | control group. |
| b. | experimental group. |
| c. | dependent group. |
| d. | independent group. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 6
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | Beneficence |
| b. | Justice |
| c. | Respect for persons |
| d. | Veracity |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 3
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
| a. | Healthy subjects |
| b. | Healthy and ill subjects |
| c. | Subjects with the disease the drug will treat |
| d. | Subjects with other diseases |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 6
TOP: Nursing Process: Nursing Intervention
MSC: NCLEX: Management of Client Care
| a. | Phase I |
| b. | Phase II |
| c. | Phase III |
| d. | Phase IV |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 4
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
ORDER NOW FOR A CUSTOM-WRITTEN, PLAGIARISM-FREE PAPER WITH ALL INSTRUCTIONS FOLLOWED
| a. | Children cannot give consent, so clinical drug trials are not performed on children. |
| b. | Children can only be subjects in quasi-experimental clinical studies. |
| c. | Data from adult clinical drug trials can be extrapolated to children. |
| d. | Federal law requires that drugs for children be tested on children. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 8
TOP: Nursing Process: N/A MSC: NCLEX: Management of Client Care
IHP 310-Drug Development and Ethical Considerations
| a. | Ask another nurse to observe and cosign wasting the remaining drug from the vial. |
| b. | Keep the remaining amount in the patient’s drawer to give at the next dose. |
| c. | Record the amount unused in the patient’s medication record. |
| d. | Dispose of the vial with the remaining drug into a locked collection box. |
ANS:
DIF: Cognitive Level: Applying (Application) REF: p. 8
TOP: Nursing Process: Nursing Intervention
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | is a registered trademark. |
| b. | is always capitalized. |
| c. | is related to the drug’s chemical structure. |
| d. | is nonproprietary. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 11
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | They contain the same inert ingredients as brand-name drugs. |
| b. | They have chemical structures that are identical to proprietary drugs. |
| c. | They tend to be less expensive than brand-name drugs. |
| d. | They undergo extensive testing before they are marketed. |
ANS:
DIF: Cognitive Level: Applying (Application) REF: p. 11
TOP: Nursing Process: Nursing Intervention: Patient Teaching
MSC: NCLEX: Management of Client Care
| a. | is a controlled substance. |
| b. | is approved by the FDA. |
| c. | is available in generic form. |
| d. | meets quality and safety standards. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 7
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | “Drugs are tested on adults and safe doses for children are based on weights compared to adult weights.” |
| b. | “Drugs are deemed safe for children over time when repeated use proves effectiveness and safety.” |
| c. | “Drugs are tested for both efficacy and safety in children in order to be marketed for pediatric use.” |
| d. | “Drugs are tested on children in postmarketing studies and on a limited basis.” |
ANS:
DIF: Cognitive Level: Applying (Application) REF: p. 9
TOP: Nursing Process: Nursing Intervention
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | Drug Regulation and Reform Act |
| b. | FDA Amendments Act |
| c. | Nurse Practice Acts |
| d. | The Controlled Substances Act |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 9
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | C-I |
| b. | C-II |
| c. | C-III |
| d. | C-V |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 9
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
| a. | C-II |
| b. | C-III |
| c. | C-IV |
| d. | C-V |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: p. 9
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies
IHP 310-Drug Development and Ethical Considerations
MULTIPLE RESPONSE
| a. | To ensure a drug has accurate labeling. |
| b. | To ensure a drug is affordable. |
| c. | To ensure a drug is effective. |
| d. | To ensure a drug is free from adverse reactions. |
| e. | To ensure a drug is tested for harmful effects. |
ANS:
DIF: Cognitive Level: Understanding (Comprehension) REF: pp. 8-9
TOP: Nursing Process: N/A
MSC: NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies